A citation-based method for searching scientific literature

Anthony Markham. Drugs 2021
Times Cited: 15







List of co-cited articles
72 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang,[...]. Lancet Respir Med 2021
38
53

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
287
40

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
261
33

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
184
26

MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
79
26

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G S Mortimer, Justin I Odegaard, Elizabeth A Harrington, Juyoung Lee, Taehyang Lee,[...]. Cancer Discov 2019
87
26

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K Amatya, Mallorie H Fiero, Pallavi S Mishra-Kalyani, Whitney S Helms, Claire E Myers, Amy M Skinner,[...]. Clin Cancer Res 2022
18
20

Tepotinib: First Approval.
Anthony Markham. Drugs 2020
26
20


Capmatinib: First Approval.
Sohita Dhillon. Drugs 2020
34
20

Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Yung-Jue Bang, Wu-Chou Su, Martin Schuler, Do-Hyun Nam, Wan Teck Lim, Todd M Bauer, Analia Azaro, Ronnie Tung Ping Poon, David Hong, Chia-Chi Lin,[...]. Cancer Sci 2020
28
20

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer.
Xiao-Hong Xie, Ze-Jiang Zhan, Yin-Yin Qin, Ju-Hong Jiang, Wei-Qiang Yin, Rong-Hui Zheng, Shi-Yue Li, Cheng-Zhi Zhou. Front Oncol 2021
5
60

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.
Chao Zhang, Shao-Lei Li, Qiang Nie, Song Dong, Yang Shao, Xue-Ning Yang, Yi-Long Wu, Yue Yang, Wen-Zhao Zhong. J Thorac Oncol 2019
38
20

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
Julia K Rotow, Gavitt A Woodard, Anatoly Urisman, Caroline E McCoach, Trever G Bivona, Brett M Elicker, David M Jablons, Collin M Blakely. Clin Lung Cancer 2019
6
50

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
Wen-Zhao Zhong, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng,[...]. J Clin Oncol 2019
115
20

Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
Bo Shen, Feixiang Wu, Jiazhou Ye, Rong Liang, Ruping Wang, Ruoying Yu, Xue Wu, Yang W Shao, Jifeng Feng. Future Oncol 2019
4
50


A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
13
15

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.
Fausto Petrelli, Rosa Berenato, Luca Turati, Alessia Mennitto, Francesca Steccanella, Marta Caporale, Pierpaolo Dallera, Filippo de Braud, Ezio Pezzica, Maria Di Bartolomeo,[...]. J Gastrointest Oncol 2017
59
13

c-Met targeting in advanced gastric cancer: An open challenge.
Luigi Marano, Rita Chiari, Alessio Fabozzi, Ferdinando De Vita, Virginia Boccardi, Giandomenico Roviello, Roberto Petrioli, Daniele Marrelli, Franco Roviello, Alberto Patriti. Cancer Lett 2015
50
13


Targeting MET in cancer: rationale and progress.
Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier, George Vande Woude. Nat Rev Cancer 2012
13


Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer.
Yang Shu, Weihan Zhang, Qianqian Hou, Linyong Zhao, Shouyue Zhang, Jiankang Zhou, Xiaohai Song, Yan Zhang, Dan Jiang, Xinzu Chen,[...]. Nat Commun 2018
71
13


KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study.
N C T van Grieken, T Aoyama, P A Chambers, D Bottomley, L C Ward, I Inam, T E Buffart, K Das, T Lim, B Pang,[...]. Br J Cancer 2013
64
13

RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
Tetsuo Ushiku, Shumpei Ishikawa, Miwako Kakiuchi, Atsushi Tanaka, Hiroto Katoh, Hiroyuki Aburatani, Gregory Y Lauwers, Masashi Fukayama. Gastric Cancer 2016
39
13

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
13

Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells.
Takatsugu Ishimoto, Keisuke Miyake, Tannistha Nandi, Masakazu Yashiro, Nobuyuki Onishi, Kie Kyon Huang, Suling Joyce Lin, Ramnarayanan Kalpana, Su Ting Tay, Yuka Suzuki,[...]. Gastroenterology 2017
111
13

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim,[...]. J Clin Oncol 2021
39
13

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
Jing Zhang, Lei Guo, Xiuyun Liu, Wenbin Li, Jianming Ying. Oncotarget 2017
13
15

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
13

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
401
13

Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
Therese Seidlitz, Yi-Ting Chen, Heike Uhlemann, Sebastian Schölch, Susan Kochall, Sebastian R Merker, Anna Klimova, Alexander Hennig, Christine Schweitzer, Kristin Pape,[...]. Gastroenterology 2019
30
13

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Xiaoqiao Liu, Min Gew Choi, Kyung Kim, Kyoung-Mee Kim, Seung Tae Kim, Se Hoon Park, Razvan Cristescu, Senaka Peter, Jeeyun Lee. Pathol Res Pract 2020
44
13

PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Lihu Gu, Manman Chen, Dongyu Guo, Hepan Zhu, Wenchao Zhang, Junhai Pan, Xin Zhong, Xinlong Li, Haoran Qian, Xianfa Wang. PLoS One 2017
133
13

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry,[...]. Lancet 2014
13

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
E Van Cutsem, Y-J Bang, W Mansoor, R D Petty, Y Chao, D Cunningham, D R Ferry, N R Smith, P Frewer, J Ratnayake,[...]. Ann Oncol 2017
120
13

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
302
13

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
13

Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.
Haisheng Zhang, Antje Schaefer, Yichen Wang, Richard G Hodge, Devon R Blake, J Nathaniel Diehl, Alex G Papageorge, Matthew D Stachler, Jennifer Liao, Jin Zhou,[...]. Cancer Discov 2020
52
13

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Atsushi Ohtsu, Manish A Shah, Eric Van Cutsem, Sun Young Rha, Akira Sawaki, Sook Ryun Park, Ho Yeong Lim, Yasuhide Yamada, Jian Wu, Bernd Langer,[...]. J Clin Oncol 2011
819
13

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko,[...]. Lancet Oncol 2017
191
13

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
309
13

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Florian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, Pamela Salman, Sang Cheul Oh, György Bodoky, Galina Kurteva, Constantin Volovat, Vladimir M Moiseyenko, Vera Gorbunova,[...]. Lancet Oncol 2013
599
13

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
U Sahin, Ö Türeci, G Manikhas, F Lordick, A Rusyn, I Vynnychenko, A Dudov, I Bazin, I Bondarenko, B Melichar,[...]. Ann Oncol 2021
55
13


E-cadherin germline mutations in familial gastric cancer.
P Guilford, J Hopkins, J Harraway, M McLeod, N McLeod, P Harawira, H Taite, R Scoular, A Miller, A E Reeve. Nature 1998
13

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, Kyoung-Mee Kim, Jason C Ting, Swee Seong Wong, Jiangang Liu, Yong Gang Yue, Jian Wang, Kun Yu,[...]. Nat Med 2015
13

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero,[...]. J Clin Oncol 2016
368
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.